Tyra Biosciences (TYRA)
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United...
- Open
- 24.510
- High
- 29.560
- Low
- 24.510
- Prev. Close
- 24.860
- Volume
- 1.86M
- Turnover
- 52.91M
- Avg Price
- 28.375
- Bid/Ask Ratio
- --
- Amplitude
- 20.31%
- 52wk High
- 40.650
- Volume Ratio
- 3.93
- Turnover Ratio
- 7.44%
Tyra Biosciences Analyst Rating
View moreForecast & Rating
Sep 4, 2026Price forecast
$50.8277.38%
Forecast & RatingStrong buy
15analysts
- Strong buy80.00%
- Buy13.33%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · 2 minutes ago
Is Tyra Biosciences (TYRA) Undervalued As SURF302 Data Expectations Lift Interest?
- Top Gainers&Losers · 1 day ago, 10:00 PM
Top 10 US Stock Gainers (9.4)
- Tip Ranks · 1 day ago, 03:15 PM
Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45
- PUBT · 2 days ago, 12:01 PM
Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9
- StockTitan · 2 days ago, 04:00 AM
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 | TYRA Stock News
